Recital 6, Decision_act (EU) 2008/55

In forcesince 20 Dec 2007

Meticilline-resistant Staphylococcus aureus (MRSA) infections have been recognised as an important risk in hospitals for several decades. MRSA is resistant to the most commonly used antibiotics and it is particularly dangerous for patients with a decreased immunity. The number of deaths attributed to MRSA in the United Kingdom has been estimated at around 3000 per year. The costs for treatment per patient are estimated at EUR 12000 to 15000. Additional expenses are incurred due to hygiene and control programmes to prevent or limit the infection in hospitals.